Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
118 studies found for:    "CINJ" OR "Cancer Intitute of New Jersey" | Open Studies | United States, New Jersey
Hide Display Options
Download search resultsDownload the search results for:
"CINJ" OR "Cancer Intitute of New Jersey" | Open Studies | United States, New Jersey (118 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
41 Recruiting Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
Study Type: Interventional
Phase: Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Number Enrolled: 450
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02193282
42 Recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Conditions: Ductal Breast Carcinoma In Situ;   Estrogen Receptor and/or Progesterone Receptor Positive;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Multicentric Breast Carcinoma;   Multifocal Breast Carcinoma;   Synchronous Bilateral Breast Carcinoma
Interventions: Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate
Study Type: Interventional
Phase: Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 10000
Gender: Female
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01272037
43 Recruiting S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Number Enrolled: 1900
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01674140
44 Recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Clear Cell Adenocarcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Mucinous Adenocarcinoma;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinofibroma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
Study Type: Interventional
Phase: Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 1038
Gender: Female
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT00565851
45 Recruiting Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
Conditions: Stage II Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Procedure: Axillary Lymph Node Dissection (ALND);   Radiation: Nodal Radiation Therapy;   Radiation: Axillary Radiation Therapy
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 2918
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01901094
46 Recruiting Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Conditions: Recurrent Glioblastoma;   Recurrent Adult Brain Tumor;   Gliosarcoma
Interventions: Biological: HSPPC-96;   Drug: bevacizumab
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH / Industry
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 165
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01814813
47 Recruiting Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: photon beam radiation therapy;   Radiation: proton beam radiation therapy;   Drug: temozolomide;   Other: laboratory biomarker analysis
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 576
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02179086
48 Recruiting Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
Conditions: Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Erlotinib Hydrochloride;   Drug: Etoposide;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
Study Type: Interventional
Phase: Phase 2
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 234
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01822496
49 Recruiting Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Conditions: Micropapillary Serous Carcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Tamoxifen Citrate;   Drug: Topotecan Hydrochloride;   Drug: Trametinib
Study Type: Interventional
Phases: Phase 2 / Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Crossover Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 250
Gender: Female
Age: 19 Years and older   (Adult, Senior)
NCT Number: NCT02101788
50 Recruiting Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: palliative surgery;   Procedure: therapeutic conventional surgery;   Radiation: palliative radiation therapy;   Radiation: radiation therapy
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 880
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01242800
51 Recruiting Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
Conditions: Lymphoma;   Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure;   Other: informational intervention
Study Type: Observational
Phase:
Funder Type: Other / NIH
Study Design: Observational Model: Case-Only;   Time Perspective: Prospective
Number Enrolled: 250
Gender: Both
Age: up to 21 Years   (Child, Adult)
NCT Number: NCT01000753
52 Recruiting Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma
Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Study Type: Observational
Phase:
Funder Type: Other / NIH
Study Design: Time Perspective: Retrospective
Number Enrolled: 1000
Gender: Both
Age: up to 120 Years   (Child, Adult, Senior)
NCT Number: NCT00899275
53 Recruiting Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Navitoclax;   Drug: Osimertinib;   Other: Pharmacological Study
Study Type: Interventional
Phase: Phase 1
Funder Type: NIH
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 50
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02520778
54 Recruiting Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Metastatic Melanoma;   Recurrent Melanoma;   Solid Neoplasm;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Other: Laboratory Biomarker Analysis;   Biological: Navitoclax;   Other: Pharmacological Study;   Drug: Trametinib
Study Type: Interventional
Phases: Phase 1 / Phase 2
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 68
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01989585
55 Recruiting Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Tumor;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Other: Pharmacological Study
Study Type: Interventional
Phase: Phase 2
Funder Type: NIH
Study Design: Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 70
Gender: Female
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02345265
56 Recruiting Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy
Condition: Adult Acute Myeloid Leukemia in Remission
Interventions: Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
Study Type: Interventional
Phase: Phase 2
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Crossover Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 80
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02275533
57 Recruiting Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: concomitant temozolomide (TMZ);   Radiation: radiotherapy;   Drug: procarbazine;   Drug: adjuvant temozolomide (TMZ);   Drug: CCNU;   Drug: vincristine
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 360
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT00887146
58 Recruiting The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)
Condition: Breast Neoplasms
Intervention: Other: endocrine therapy alone without radiotherapy
Study Type: Interventional
Phase:
Funder Type: Other
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 200
Gender: Female
Age: 50 Years to 69 Years   (Adult, Senior)
NCT Number: NCT02400190
59 Recruiting Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Condition: Kidney Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: sunitinib malate
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 100
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01164228
60 Recruiting A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
Condition: Early Stage HER2+ Breast Cancer
Interventions: Drug: Neratinib;   Drug: Loperamide
Study Type: Interventional
Phase: Phase 2
Funder Type: Industry
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 120
Gender: Both
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02400476

First Page    Show previous page of results Previous Page (21-40) Studies Shown (41-60) Next Page (61-80) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.